Rupture of totally implantable central venous access devices (Intraports) in patients with cancer: Report of four cases

World Journal of Surgical Oncology

Volumn 2, Issue , 2004, Pages

  Filippou, Dimitrios K ^a,b   Tsikkinis, Christoforos ^a,c   Filippou, Georgios K ^b   Nissiotis, Athanasios ^a,b   Rizos, Spiros ^a,b  

^a Department of Surgical Oncology   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c Metaxas Anticancer Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ENOXAPARIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL VENOUS CATHETER; COLON CANCER; CONTROLLED STUDY; DEVICE REMOVAL; FEMALE; FEMUR; FLUOROSCOPY; FOLLOW UP; HEART RIGHT VENTRICLE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PATIENT CARE; POSTOPERATIVE COMPLICATION; SURGICAL APPROACH; THROMBOEMBOLISM; TIME; VASCULAR ACCESS;

EID: 13844272113     PISSN: 14777819     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7819-2-36     Document Type: Article

References (14)

1. Biffi R, Corrado F, de Braud F, de Lucia F, Scarpa D, Testori A, Orsi F, Bellomi M, Mauri S, Aapro M, Andreoni B: Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumors. Experience of 178 cases using a single type of device. Eur J Cancer 1997, 33:1190-1194.
2. Kurul S, Saip P, Aydin T: Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 2002, 3:684-692.
3. Talfer S, Conessa C, Herve S, Rogouet E, de Rotalier P, Poncet JL: [Complications with totally implantable venous access device. A retrospective of 116 cases]. Presse Med 2003, 32: 263-1268. French
4. Aubaniac R: L' injection intraveineuse sous-claviculaire: Avantages et technique. Presse Med 1952, 60:1456-1458.
5. Yedlicka JW Jr, Carlson JE, Hunter DW, Castaneda-Zuniga WR, Amplatz K: Nitinol goose-neck snare for removal of foreign bodies. Experimental study and clinical evaluation. Radiology 1991, 178:691-693.
6. Vasquez RM, Brodski EG: Primary and secondary malposition of silicon central venous catheters. Acta Anaesthesiol Scand 1985, 81:22-25.
7. Koulas S, Karahalios N, Kotzias N, Filippou D, Efthimiadou S, Nissiotis A: Infectious and other complications in totally implantable venous access port catheters. In the Proceedings of the Sixth Annual Congress of Intensive Care Medicine, 9-10 October 1997; Athens, Greece. Produced by the Hellenic Society of Intensive Medicine 1997:41.
8. Brothers TE, Von Moll LK, Niederhuber JE, Roberts JA, Walker-Andrews S, Ensminger WD: Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet 1988, 166:295-301.
9. Marie O, Leverger G, Douard MC, Mourey F, Roche A, Eurin B: Migration intravsculaire de fragments de catheters veineux centraux. Presse Med 1986, 15:1270-1272.
10. Ballarini C, Intra M, Pisani Ceretti A, Cordovana A, Pagani M, Farina G, Perrone S, Tomirotti M, Scanni A, Spina GP: Complications of subcutaneous infusion port in the general oncology population. Oncology 1999, 56:97-102.
11. Tazzioli G, Roncaglia G: Impiego dei sistemi venosi totalmente impiantabili nelle terapie infusive di lunga durata. Chirurgia 1995, 8:93-95.
12. Barrios CH, Zuke JE, Blaes B, Hirsch JD, Lyss AP: Evaluation of an implantable venous access system in a general oncology population. Oncology 1992, 49:474-478.
13. Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, Nole F, Andreoni B: Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol 1998, 9:767-773.
14. Biffi R, Pozzi S, Agazzi A, Pace U, Floridi A, Cenciarelli S, Peveri V, Cocquio A, Andreoni B, Martinelli G: Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol 2004, 15:296-300.